Ainnova's AI-based platform can detect diabetic retinopathy in less than five seconds.
In a feature on advancing early disease detection, Ainnova Tech's AI-based platform was highlighted for its ability to detect diabetic retinopathy in less than five seconds — bringing fast, accessible screening to primary care.
VisionAI analyzes retinal images with deep learning to flag early signs of disease, helping clinicians refer patients in time.
VisionAI is Ainnova's AI-powered platform for detecting diabetic retinopathy and other retinal diseases from a simple, non-invasive fundus eye test — delivering results in seconds.
By bringing fast, accurate screening to primary care, VisionAI helps clinicians refer patients in time to prevent avoidable vision loss.
Ainnova Tech is a healthcare technology company focused on revolutionizing early disease detection using artificial intelligence. Its platform, VisionAI, analyzes retinal images to detect early markers of diseases such as diabetic retinopathy — with a growing portfolio spanning cardiovascular, metabolic, liver and kidney risk. Ainnova is dedicated to making healthcare more proactive, accessible and efficient.
Source: Featured in Omnia Health Insights ↗
Contact: Ainnova Tech — info@ainnovatech.com